Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

Patients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The current study will test the ability of an anti-inflammatory medicine (anakinra) to block the inflammation in the body during and after a heart attack.

NCT Number	NCT05177822
Lead Sponsor	Virginia Commonwealth University Collaborators: National Institute on Aging (NIA), University of Virginia
Conditions	Heart Failure
Enrollment	84 participants
Start Date	2022-05-24
Primary Completion	2027-02-22 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-06